
Sonnet BioTherapeutics, Inc. (NASDAQ: SONN) related to its merger with Rorschach I LLC. Upon completion of the proposed transaction, Sonnet shareholders will own approximately 1% of the combined company.
Sonnet BioTherapeutics, Inc. (NASDAQ: SONN) related to its merger with Rorschach I LLC. Upon completion of the proposed transaction, Sonnet shareholders will own approximately 1% of the combined company.